New immunotherapy shows promise for advanced liver cancer in asian patients
Disease control
Terminated
This study tests an experimental immunotherapy called AlloStim against standard treatments (Sorafenib, Lenvatinib, or FOLFOX4) in 150 Asian adults with advanced liver cancer that cannot be treated with surgery or local therapies. The main goal is to see if AlloStim helps patients…
Phase: PHASE2, PHASE3 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC